A Phase 2a trial of niclosamide (FW-420) for the treatment of for Grade 1 and Grade 2 immune checkpoint inhibitor-associated colitis (ICI-AC) and diarrhea in oncology patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 29 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 May 2024 According to an Entero Therapeutics media release, First Wave Biopharma has changed its name to Entero Therapeutics.
16 Nov 2021 According to a First Wave Biopharma media release, the company expect to initiate this trial in 2022.
21 Oct 2021 According to a First Wave Biopharma media release, the committee members also include 4) David Faleck, M.D., Assistant Professor of Medicine at Weill Medical College and an attending physician in the Gastroenterology, Hepatology and Nutrition Service at Memorial Sloan Kettering Cancer Center (MSK).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com